CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

Imetelstat, a first-in-class telomerase inhibitor, showed high rates of durable transfusion independence (TI) across all lower-risk myelodysplastic syndrome (LR-MDS) patient subtypes in the phase 3 IMerge trial. Here, the impact of imetelstat on patient-reported outcomes (PROs) and health care resource utilization (HCRU) was explored.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Sekeres, V. Santini, M. Diez-Campelo, R. Komrokji, P. Fenaux, M. Savona, Y. Madanat, D. Valc árcel-Ferreiras, T. Illmer, A. Jonášová, P. Bělohlávková, A. Regnault, K. Creel, N. Sengupta, L. Sherman, T. Berry, S. Dougherty, S. Shah, Q. Xia, L. Su Source Type: research